Kymera Therapeutics
KYMR
115 hedge funds and large institutions have $2.04B invested in Kymera Therapeutics in 2021 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 62 increasing their positions, 23 reducing their positions, and 16 closing their positions.
2,285% more call options, than puts
Call options by funds: $13.1M | Put options by funds: $549K
170% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 23
58% more capital invested
Capital invested by funds: $1.29B → $2.04B (+$747M)
31% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 16
8.9% more ownership
Funds ownership: 58.97% → 67.86% (+8.9%)
5% more funds holding
Funds holding: 110 → 115 (+5)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$95.1M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$80.5M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$49.7M |
| 4 |
BlackRock
New York
|
+$34.3M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DIC
Deer IX & Co
Larchmont,
New York
|
-$35.9M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$25.2M |
| 3 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$23.3M |
| 4 |
TOCUITCONY
Trustees of Columbia University in the City of New York
New York
|
-$13.5M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$5.81M |
KYMR Hedge Fund Activity: Q3 2021 in Review
115 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Kymera Therapeutics (KYMR) for Q3 2021, worth a combined $2.04B — up 58% from $1.29B a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new KYMR positions and 16 closed out — a net gain of 5 holders — while 62 added to existing stakes and 23 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $95.1M. The largest seller was Deer IX & Co, cutting an estimated $35.9M.
- 115 institutional investors held Kymera Therapeutics (KYMR) as of Q3 2021, up from 110 in Q2 2021.
- Funds reported $2.04B of Kymera Therapeutics stock for Q3 2021, up 58% quarter-over-quarter.
- 21 funds opened new Kymera Therapeutics positions in Q3 2021 and 16 closed out, a net change of +5 holders.
- The largest Kymera Therapeutics buyer in Q3 2021 was Wellington Management Group, an estimated $95.1M added.
- The largest Kymera Therapeutics seller in Q3 2021 was Deer IX & Co, an estimated $35.9M sold.
Based on aggregated 13F filings for Q3 2021.